EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieKlinische Studie (Phase III)Multizentrische Studie

Pembrolizumab versus placebo as adjuvant therapy in resected stage IIB or IIC melanoma: Long-term follow-up, crossover, and rechallenge with pembrolizumab in the phase III KEYNOTE-716 study

Jason J Luke, Paolo A Ascierto, Muhammad A Khattak, Piotr Rutkowski, Michele Del Vecchio, Francesco Spagnolo, Jacek Mackiewicz, Luis de la Cruz Merino, Vanna Chiarion-Sileni, John M Kirkwood, Caroline Robert, Dirk Schadendorf und 9 weitere

European Journal of Cancer · 2025-05 · 220 · 115381

DOI: 10.1016/j.ejca.2025.115381 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift European Journal of Cancer, 2025-05. Verfasst von Jason J Luke und 20 weiteren Autor:innen. Beteiligte Einrichtung: UPMC Hillman Cancer Center and University of Pittsburgh, Pittsburgh, PA, USA. Electronic address: lukejj@upmc.edu. Hauptthemen laut MEDLINE: Antibodies, Monoclonal, Humanized, Antineoplastic Agents, Immunological, Melanoma, Neoplasm Recurrence, Local. Die Arbeit wurde bisher 19-mal zitiert (Crossref) und nennt 10 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antibodies, Monoclonal, HumanizedAntineoplastic Agents, ImmunologicalMelanomaNeoplasm Recurrence, LocalSkin NeoplasmsAdultAgedFemaleHumansMaleMiddle AgedChemotherapy, AdjuvantCross-Over StudiesDouble-Blind MethodFollow-Up StudiesNeoplasm Staging

Stichwörter der Autor:innen

Adjuvant therapyImmune checkpoint inhibitorsMelanomaPembrolizumabProgrammed cell death protein 1

Substanzen

Antibodies, Monoclonal, HumanizedAntineoplastic Agents, Immunologicalpembrolizumab

Autor:innen und Institutionen

  • UPMC Hillman Cancer Center and University of Pittsburgh, Pittsburgh, PA, USA. Electronic address: lukejj@upmc.edu.
  • Istituto Nazionale Tumori IRCCS Fondazione Pascale, Naples, Italy.
  • Fiona Stanley Hospital and Edith Cowan University, Perth, WA, Australia.
  • Maria Sklodowska-Curie National Research Institute of Oncology, Warsaw, Poland.
  • Fondazione IRCCS Istituto Nazionale dei Tumori, Milano, Italy.
  • IRCCS Ospedale Policlinico San Martino, Genoa, Italy.

Zitieren

APA

Luke, J. J., Ascierto, P. A., Khattak, M. A., Rutkowski, P., Del Vecchio, M., Spagnolo, F., Mackiewicz, J., Merino, L. C., Chiarion-Sileni, V., Kirkwood, J. M., Robert, C., Schadendorf, D., de Galitiis, F., Carlino, M. S., Dummer, R., Mohr, P., Odeleye-Ajakaye, A., Fukunaga-Kalabis, M., Krepler, C., …, & Long, G. V. (2025). Pembrolizumab versus placebo as adjuvant therapy in resected stage IIB or IIC melanoma: Long-term follow-up, crossover, and rechallenge with pembrolizumab in the phase III KEYNOTE-716 study. European Journal of Cancer, 220, 115381. https://doi.org/10.1016/j.ejca.2025.115381

Vancouver

Luke JJ, Ascierto PA, Khattak MA, Rutkowski P, Del Vecchio M, Spagnolo F, et al. Pembrolizumab versus placebo as adjuvant therapy in resected stage IIB or IIC melanoma: Long-term follow-up, crossover, and rechallenge with pembrolizumab in the phase III KEYNOTE-716 study. European Journal of Cancer. 2025;220:115381. doi:10.1016/j.ejca.2025.115381

BibTeX
@article{Luke2025,
  author = {Luke, Jason J and Ascierto, Paolo A and Khattak, Muhammad A and Rutkowski, Piotr and Del Vecchio, Michele and Spagnolo, Francesco and Mackiewicz, Jacek and Merino, Luis de la Cruz and Chiarion-Sileni, Vanna and Kirkwood, John M and Robert, Caroline and Schadendorf, Dirk and de Galitiis, Federica and Carlino, Matteo S and Dummer, Reinhard and Mohr, Peter and Odeleye-Ajakaye, Amos and Fukunaga-Kalabis, Mizuho and Krepler, Clemens and Eggermont, Alexander M M and Long, Georgina V},
  title = {Pembrolizumab versus placebo as adjuvant therapy in resected stage IIB or IIC melanoma: Long-term follow-up, crossover, and rechallenge with pembrolizumab in the phase III KEYNOTE-716 study},
  journal = {European Journal of Cancer},
  year = {2025},
  volume = {220},
  pages = {115381},
  doi = {10.1016/j.ejca.2025.115381}
}
Kostenlos starten →